|
US2021085686A1
|
|
Delivery of active agents using nanofiber webs
|
|
CA3111100A1
|
|
Taurolidine treatment for myc-expressing tumors in mammalian bodies
|
|
US2019381060A1
|
|
Taurolidine treatment for myc-expressing tumors in mammalian bodies
|
|
US2019381058A1
|
|
Methods and compositions for treating neuroblastoma in a juvenile mammalian body
|
|
AU2019330954A1
|
|
Neuroblastoma treatment with taurolidine hydrolysis products
|
|
CA3111015A1
|
|
Methods and compositions for treating neuroblastoma in a juvenile mammalian body
|
|
US2019381059A1
|
|
Neuroblastoma treatment with taurolidine hydrolysis products
|
|
WO2019126750A1
|
|
Pharmaceutical compositions and methods for treating keloids hypertrophic scars and wounds, and for providing improved skin care
|
|
EP3727393A2
|
|
Methods and pharmaceutical compositions for treating candida auris in blood
|
|
WO2018175777A1
|
|
Use of an injectable antimicrobial composition for the prevention and/or treatment of osteoarthritis
|
|
US2018207103A1
|
|
Use of an injectable antimicrobial composition for the prevention and/or treatment of osteoarthritis
|
|
CN110573192A
|
|
antimicrobial compositions comprising antimicrobial hydrogels effective against mature biofilms
|
|
WO2018129061A1
|
|
Antimicrobial delivery system for the prevention and treatment of infections in the colon
|
|
WO2018126133A1
|
|
Skin-penetrating formulation of taurolidine
|
|
US2018117058A1
|
|
Skin-penetrating formulation of taurolidine
|
|
KR20180126523A
|
|
On-site sterilizer and vascular connector kit
|
|
CN108778339A
|
|
Therapeutic nano particle for treating neuroblastoma and other cancers
|
|
AU2016334086A1
|
|
Skin-penetrating formulation of taurolidine
|
|
AU2016315779A1
|
|
Delivery of active agents using nanofiber webs
|
|
US2017056561A1
|
|
Compositions for the treatment of joints
|
